INNOVIVA, INC. Secured Long-term Debt, Noncurrent
INNOVIVA, INC. (INVA) had Secured Long-term Debt, Noncurrent of $400.85 million as of 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:SecuredLongTermDebt · last filed 2017-08-08
- 2017-06-30: Secured Long-term Debt, Noncurrent $400.85M.
- 2017-03-31: Secured Long-term Debt, Noncurrent $464.60M.
- 2016-12-31: Secured Long-term Debt, Noncurrent $470.74M.
- 2016-09-30: Secured Long-term Debt, Noncurrent $477.91M.
| Period end | Secured Long-term Debt, Noncurrent | Secured Long-term Debt, Noncurrent as first filed |
|---|---|---|
| 2017-06-30 | $400.85M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $464.60M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $470.74M 10-Q · filed 2017-08-08 | |
| 2016-09-30 | $477.91M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $480.88M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $483.39M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $482.14M 10-K · filed 2017-02-28 | $493.16M 10-K · filed 2016-02-24 |
| 2015-09-30 | $488.98M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $483.36M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $476.95M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $470.53M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $450.00M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $450.00M 10-Q · filed 2014-08-07 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |